Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1721309 | 0.94 | CYP4F2 (0.42) | CYP4F2CYP4A11DGAT1TDP1CA1 | |
| SCHEMBL23970490 | 0.92 | CYP4F2 (0.44) | CYP4F2CYP4A11DGAT1TDP1ACLY | |
| SCHEMBL23971207 | 0.92 | CYP4F2 (0.44) | CYP4F2CYP4A11DGAT1TDP1ACLY | |
| SCHEMBL3041732 | 0.87 | DGAT1 (0.41) | CYP4F2CYP4A11DGAT1CA2GAA | |
| SCHEMBL22016458 | 0.85 | CYP4F2 (0.52) | CYP4F2CYP4A11DGAT1TDP1CA1 | |
| SCHEMBL30690424 | 0.82 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL28489181 | 0.81 | CYP4F2 (0.44) | CYP4F2CYP4A11DGAT1TDP1CA1 | |
| SCHEMBL4122676 | 0.81 | CYP4F2 (0.40) | CYP4F2CYP4A11DGAT1ACLY | |
| SCHEMBL17756699 | 0.79 | CYP4F2 (0.47) | CYP4F2CYP4A11DGAT1MEN1KMT2A | |
| SCHEMBL17746739 | 0.79 | CYP4F2 (0.61) | CYP4F2CYP4A11DGAT1TDP1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | GENFIT (FR) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079696-A1 | Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses | AADAC, NAT1, PARN | CYP4F2 1471/4885CYP4A11 1131/4885DGAT1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.